In a move to better enhance operational efficiency and strategic focus, the Board initiated a leadership review to better support BenevolentAI's ambitious growth plans. The results of the review include Ms.
The Company is intensifying its efforts to capitalise on the expanding opportunities within the rapidly maturing 'techbio' sector. BenevolentAI's strong momentum is underscored by last week's successful integration of a novel target in Systemic Lupus Erythematosus into
The Board's review further highlighted the need to adopt a more dynamic and entrepreneurial approach across the Company's leadership, business development activities, and internal management structures. These changes are designed to expand the Company's market share in the AI-driven drug discovery sector, accelerate the development of its internal pipelines, and forge new strategic collaborations.
Dr
Public disclosure of inside information in accordance with article 17(1) of the Regulation (EU) No 596/2014 on market abuse (Market Abuse Regulation)
Contact:
Dr.
Email: investors@benevolent.ai
Tel: +44 (0) 203 781 9360
Email: press@benevolent.ai
Tel: +44 (0) 203 781 9360
About BenevolentAI
At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent Platform that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery.
The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like
(C) 2024 Electronic News Publishing, source